Clinical study of apatinib mesylate tablets combined with tegafur in the treatment of advanced gastric cancer in elderly patients
Objective To study the effect of apatinib mesylate tablets combined with tegafur in the treatment of advanced gastric cancer in elderly patients.Methods A total of 60 elderly patients with advanced gastric cancer were selected,and all subjects were randomly coded.The sequence number of patients in the control group was confirmed to be 1-30,and the sequence number of patients in the study group was confirmed to be 31-60.Patients in control group were treated with tegafur,and patients in the study group received apatinib mesylate tablets combined with tegafur.The clinical effects,occurrence of adverse reactions and survival status at the 1st,2nd and 3rd year after treatment were compared between the two groups.Results The remission rate of 53.33%and control rate of 80.00%in the study group were higher than 16.67%and 46.67%in the control group(P＜0.05).The incidence of adverse reactions was 26.67%in the study group and 20.00%in the control group,and there was no statistical significance in comparison(P＞0.05).At the 2nd and 3rd year,20 cases(66.67%)and 18 cases(60.00%)survived in the control group,while 27 cases(90.00%)and 25 cases(83.33%)survived in the research group,and the survival rates at 1st,2nd and 3rd year after treatment in the study group were higher than those in the control group(P＜0.05).There was no statistical significance in the 1-year survival rate between the two groups(P＞0.05).Conclusion Apatinib mesylate tablets combined with tegafur can significantly alleviate and control the progression of the disease in elderly patients with advanced gastric cancer,without increasing the occurrence of adverse reactions,and prolong the survival time,which is worthy of clinical promotion.
Advanced gastric cancerApatinib mesylate tabletsTegafurDisease control statusOld age
万方数据
维普
